Grifols (GRFS) Cash from Restructuring (2022 - 2023)
Grifols (GRFS) reported Cash from Restructuring of $171022.8 for Q4 2023, up 364.68% on a YoY basis from $36804.4 in Q4 2022, and up 364.68% quarter-over-quarter from $36804.4 in Q4 2022.
Grifols (GRFS) Cash from Restructuring (2022 - 2023) Analysis & Trends
Grifols has reported Cash from Restructuring for 2 years, with the latest figure at $171022.8 in Q4 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Grifols | 6.05 Bn | 5.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 171,022.80 |
| Dec 31, 2022 | 36,804.40 |